<DOC>
	<DOCNO>NCT01012141</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Dietary supplement , phytochemical , may stop delay development prostate cancer .</brief_summary>
	<brief_title>Docetaxel With Phytochemical Treating Patients With Hormone Independent Metastatic Prostate Cancer</brief_title>
	<detailed_description>The purpose study assess pathological response rate metastatic prostate cancer patient treat : Docetaxel phytochemical</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Age &gt; 18 WHO performance status 02 Life expectancy ≥ 3 month Patients receive androgensuppressive therapy form chirurgical castration orchiectomy pulpectomy , medical LHRH agonist antagonist without antiandrogen treatment block non gonadic testosterone fraction Resulting testosteronemia &lt; 0,5 ng/ml Histologically confirm adenocarcinomia prostate cancer document hormone independant metastatic disease define : objective progression least one measurable lesion and/or evaluable lesion accord RECIST criterion /or rise PSA level ( `` rise PSA '' ) Total bilirubin ≤ upper limit normal ( ULN ) . AST ALT ≤ 1.5 time ULN . Alkaline phosphatase ≤ 2.5 time ULN . Serum creatinine &lt; 140 µmol/L creatinine clearance &gt; 60 mL/ min . Neutrophil count &gt; 2.109 L1 . Platelet count ≥ 100,000/mm3 . Hemoglobin ≥ 10 g/dL Not previous chemotherapy , except Estracyt No liver , kidney heart failure link treatment No malabsorption syndrome disease significantly affect gastrointestinal function Prior radiotherapy permetted withing four week first study treatment must &lt; 25 % bone marrow , adverse event must resolve Prior surgery permit . Age &lt; 18 History psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding , observance give informed consent Previous concomitant malignancy except basal squamous cell carcinoma skin cancer curatively treat surgery and/or radiotherapy Patients symptomatic brain metastasis Concurrent severe and/or uncontrolled comorbid medical condition Malabsorption syndrome disease significantly affect gastrointestinal function major resection stomach , proximal small bowel grade &gt; 2 dysphagia Patients uncontrolled infection History significant neurologic ( i.e . peripheral neuropathy grade &gt; 2 use NCICTC criterion v3.0 ) Patients receive NSAIDs COX2 inhibitor within three week prior start study Treatment investigational drug within 30 day prior registration Patients current regimen contain dietary phytonutrients</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>